I reckon it's better than 50:50.
the US Fed is tightening but the PBC (People's Bank of China) is easing. Also pharm/drugs companies are increasing investment into products for growth rather than low margin generics.
Ann: Dimerix Receives $8.9M R&D Tax Incentive Rebate, page-14
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $211.9M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $339.4K | 900.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 66275 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 78283 | 4 |
View Market Depth
| Last trade - 13.29pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |